Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,514.37 65.12 0.40%
S&P 500 1,879.55 7.66 0.41%
NASDAQ 4,161.46 39.91 0.97%
Ticker Volume Price Price Delta
STOXX 50 3,192.30 -7.39 -0.23%
FTSE 100 6,682.93 1.17 0.02%
DAX 9,580.03 -20.06 -0.21%
Ticker Volume Price Price Delta
NIKKEI 14,546.27 157.50 1.09%
TOPIX 1,173.81 11.31 0.97%
HANG SENG 22,509.64 -221.04 -0.97%

Illumina Unveils Strategic Roadmap for Market Expansion



  Illumina Unveils Strategic Roadmap for Market Expansion

Company Positions for Growth in Key Genomics Segments, Introduces New Workflow
                          Solutions at Investor Day

Business Wire

SAN DIEGO -- January 16, 2014

Illumina, Inc. (NASDAQ:ILMN) today unveiled a strategic roadmap for moving
next-generation sequencing (NGS) into new markets, leveraging its technology
leadership and new organizational alignment around those markets to drive
growth. During an investor day where executives presented plans for this
growth, Illumina also shared workflow innovations designed to simplify the
sequencing experience and new market solutions derived from the company’s
sample to answer technology base.

“Earlier this week we announced two transformative platforms that redefine
next-generation sequencing, with the addition of the NextSeq™ 500 System and
the HiSeq® X Ten to our market leading portfolio. Today we previewed
additional innovations that position us to seize opportunities across research
and clinical markets, as well as to deliver the industry’s simplest, most
efficient sequencing experience to our customers,” said Jay Flatley,
Illumina’s Chief Executive Officer.

Expanding the Use of Next-Generation Sequencing (NGS)

Illumina shared the following strategies and innovations around its core
market targets.

  * In reproductive health, Illumina will expand its offerings based on the
    verifi® laboratory-developed non-invasive prenatal test (NIPT), submitting
    an IVD version on the HiSeq® 2500 system for FDA premarket approval by the
    end of 2014. It also will offer an NGS-based solution for preimplantation
    genetic screening, VeriSeq™ PGS, launching initially on the MiSeq® system,
    as well as an array-based karyomapping single gene preimplantation genetic
    diagnosis (PGD) solution to identify embryos with genes associated with
    severe genetic disorders.
  * In oncology, the company previewed a targeted sequencing strategy that
    includes supporting the clinical community with content. Illumina is also
    working in collaboration with the oncology community to develop test
    guidelines and infrastructure to build actionable cancer genomics
    solutions.
  * In emerging markets, Illumina will launch a human leukocyte antigen (HLA)
    typing product in mid-2014 for laboratories seeking next-generation
    sequencing on the MiSeq® platform that will be faster, less expensive, and
    more accurate than current technologies. Additionally, the company
    introduced the MiSeq® Forensic Genomics System (MiSeq FGx), the first
    targeted forensic NGS system, which will simultaneously interrogate short
    tandem repeats and other valuable genetic markers to provide more
    comprehensive identification information from both challenging and
    standard biological samples. The complete sample to answer solution,
    including consumables and software, is expected to be available in the
    first six months of 2014.

Simplifying the Sample to Answer Experience

Illumina previewed the following products that simplify the end-user
experience for sample preparation and analytics and further solidify the
technology tool kit that can be used across markets to address customers’
needs for integration.

  * NeoPrep™  is a push-button library preparation system that provides a
    radically simpler workflow to go from DNA or RNA to libraries ready for
    sequencing. It will prepare up to 16 libraries per run, starting from as
    little as 1ng of input for some assays. The first kits for NeoPrep will be
    TruSeq PCR-Free and TruSeq Nano, with other TruSeq and Nextera kits to
    follow. NeoPrep, expected to be available summer 2014, is an important
    step on the path to offering integrated, sample to answer solutions.
  * BaseSpace® OnSite  provides the BaseSpace® experience in a simple
    informatics appliance, enabling NGS users to securely stream data directly
    to a local solution for storing, analyzing, and interpreting genomic
    sequence data. BaseSpace® Onsite represents a turnkey solution and will be
    available in the first quarter of 2014.
  * BaseSpace® Core Apps transform sequence data processing into a simple
    push-button process for the most frequently used sequencing applications.
    These highly optimized apps eliminate time spent configuring and
    maintaining software, and support RNA-sequencing, exome analysis, whole
    genome sequencing, and tumor/normal analysis. BaseSpace® Core Apps are
    available for BaseSpace® including BaseSpace® Onsite.

Paving the Way for Genomics in the Clinic

In November 2013, Illumina became the first company to receive FDA premarket
clearance for a next-generation sequencing platform with its MiSeqDx system.
Illumina will continue to pave the way for NGS in regulated markets with
further submissions to the FDA, beginning with NIPT on the HiSeq® 2500, while
also driving standards for the use of NGS in the clinic. In addition, the
company will continue to build the infrastructure and means with which to
deliver a best-in-class regulated products pipeline through its IVD
Development group.

“Illumina’s technology is already making an impact in identifying undiagnosed
diseases, and we will soon see it transforming fields like oncology and
complex disease,” said Francis deSouza, President of Illumina. “The strategic
roadmap presented today demonstrates our commitment to making NGS ubiquitous
across markets, delivering simplified and integrated solutions to our
customers, and paving the way for a new era in health care.”

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release contains forward looking statements that involve risks and
uncertainties. Examples of forward-looking statements include, but are not
limited to, statements we make regarding the expected availability dates for
new products and services and FDA submission dates and intentions for certain
products and services. Important factors that could cause actual results to
differ materially from those in any forward-looking statements include
challenges inherent in developing, manufacturing, and launching new products
and services and the other factors that are detailed in our filings with the
Securities and Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference calls, the
date and time of which are released beforehand. We do not intend to update any
forward-looking statements after the date of this release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement